Tooth enamel ESR doses and cytogenetic doses of Nagasaki atomic-bomb survivors in comparison with DS02R1 doses. (6th December 2018)

• Record Type: Journal Article
• Authors: Hirai, Yuko; Cordova, Kismet A.; Kodama, Yoshiaki; Hamasaki, Kanya; Awa, Akio A.; Tomonaga, Masao; Mine, Mariko; Cullings, Harry M.; Nakamura, Nori
• Is Part Of: International journal of radiation biology. Volume 95:Number 3(2019)
• Page Start: 321
• Page End: 328
• Publication Date: 2018-12-06
• Subjects: Biodosimetry -- electron spin resonance -- ESR -- cytogenetics -- atomic-bomb survivors -- Nagasaki; Radiation -- Physiological effect -- Periodicals; Radiobiology -- Periodicals; 571.45
• DOI: 10.1080/09553002.2019.1552807
• Languages: English
• ISSNs: 0955-3002

Abstract

Abstract: Purpose: Cancer risks for Nagasaki survivors once appeared to be lower than for Hiroshima survivors. The possibility that this was due to overestimation of the doses for the Nagasaki survivors was tested by measuring biological doses of Nagasaki survivors and comparing them with DS02R1 individual doses as previously done for Hiroshima survivors. Materials and methods: The electron spin resonance (ESR) method and cytogenetic method were used to estimate radiation doses for 24 Nagasaki survivors, and the results were compared to calculated DS02R1 doses. Results: Six factory workers and 10 other survivors showed ESR or cytogenetically estimated doses that were in reasonably good agreement with their DS02R1 doses, while one factory worker was found to have an ESR dose estimate of nearly one half of the DS02R1 dose to the eye lens (a proxy organ for teeth). A few outliers were also observed. Conclusions: Although apparently lower cancer risks were observed in the past for Nagasaki survivors when compared to Hiroshima survivors, the present results do not indicate the existence of a trend that DS02R1 doses are overestimated when compared with biologically estimated tooth or cytogenetic doses. This observation is in line with the recent disappearance of the city difference in cancer risks.